87 related articles for article (PubMed ID: 10195060)
1. Early lipodystrophy occurring during post-exposure prophylaxis.
Spenatto N; Viraben R
Sex Transm Infect; 1998 Dec; 74(6):455. PubMed ID: 10195060
[No Abstract] [Full Text] [Related]
2. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
[TBL] [Abstract][Full Text] [Related]
3. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients.
Quirino T; Niero F; Ricci E; Pusterla L; Carradori S; Gabbuti A; Iemoli E; Landonio S; Faggion I; Bonfanti P;
Antivir Ther; 2000 Sep; 5(3):195-7. PubMed ID: 11075939
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
Rabaud C; Burty C; Grandidier M; Christian B; Penalba C; Béguinot I; Jeanmaire H; May T
Clin Infect Dis; 2005 Jan; 40(2):303-5. PubMed ID: 15655751
[TBL] [Abstract][Full Text] [Related]
5. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
[TBL] [Abstract][Full Text] [Related]
6. CT appearances of HIV-related lipodystrophy syndrome.
Gellett LR; Haddon L; Maskell GF
Br J Radiol; 2001 Apr; 74(880):382-3. PubMed ID: 11387159
[TBL] [Abstract][Full Text] [Related]
7. Switching Combivir to Truvada keeps HIV undetectable, improves blood fats, fails to improve limb fat.
Proj Inf Perspect; 2008 Dec; (47):8. PubMed ID: 19227559
[No Abstract] [Full Text] [Related]
8. HIV/AIDS following sexual assault in Jamaican children and adolescents: a case for HIV post-exposure prophylaxis.
Steel-Duncan JC; Pierre R; Evans-Gilbert T; Rodriquez B; Christie CD
West Indian Med J; 2004 Oct; 53(5):352-5. PubMed ID: 15675503
[TBL] [Abstract][Full Text] [Related]
9. Zidovudine + lamivudine: new preparation. Fewer tablets required.
Prescrire Int; 1999 Apr; 8(40):39-40. PubMed ID: 10848057
[TBL] [Abstract][Full Text] [Related]
10. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
11. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
Gartland M;
Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
[TBL] [Abstract][Full Text] [Related]
12. [Increased girth, thin arms. Unusual changes in HIV therapy].
MMW Fortschr Med; 1999 Sep; 141(36):62-3. PubMed ID: 10904607
[No Abstract] [Full Text] [Related]
13. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
[TBL] [Abstract][Full Text] [Related]
14. [Lipodystrophy syndrome. After 3 years every third patient has lost his fat].
MMW Fortschr Med; 2000; 142(3 Suppl):16-7. PubMed ID: 11012290
[No Abstract] [Full Text] [Related]
15. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
[TBL] [Abstract][Full Text] [Related]
16. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors.
Walker VE; Poirier MC
Environ Mol Mutagen; 2007; 48(3-4):159-65. PubMed ID: 17358025
[No Abstract] [Full Text] [Related]
17. Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
Nerad JL; Kessler HA
Clin Infect Dis; 2001 Jun; 32(11):1635-6. PubMed ID: 11340537
[TBL] [Abstract][Full Text] [Related]
18. Lipodystrophy body-shape changes in a patient undergoing zidovudine monotherapy.
García-Benayas T; Blanco F; Gómez-Viera JM; Barrios A; Soriano V; González-Lahoz J
AIDS; 2002 May; 16(7):1087-9. PubMed ID: 11953483
[No Abstract] [Full Text] [Related]
19. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
[TBL] [Abstract][Full Text] [Related]
20. [HIV-associated lipodystrophy syndrome. Stress for the psyche and heart].
Mauss S
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():20-5. PubMed ID: 12043066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
